Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
15 September 1995 | Volume 123 Issue 6 | Pages 415-420
Objective: To determine risk factors for community-acquired and nosocomial group B streptococcal disease in adults.
Design: Case-control study.
Setting: 3 metropolitan areas in the United States with an aggregate population of 6.6 million persons.
Patients: 219 nonpregnant adults with invasive group B streptococcal infection identified by a population-based surveillance in 1991 and 1992 and 645 hospital-matched controls.
Results: The following conditions were associated with a significantly increased risk for community-acquired group B streptococcal infection after controlling for age in multivariate analysis: cirrhosis (odds ratio, 9.7 [95% CI, 3.5 to 26.9]; P < 0.001), diabetes (odds ratio, 3.0 [CI, 1.9 to 4.7]; P < 0.001), stroke (odds ratio, 3.5 [CI, 1.9 to 6.4]; P < 0.001), breast cancer (odds ratio, 4.0 [CI, 1.6 to 9.8]; P = 0.002), decubitus ulcer (odds ratio, 4.0 [CI, 1.6 to 9.8]; P = 0.002), and neurogenic bladder (odds ratio, 4.6 [CI, 1.4 to 15.1]; P = 0.01). Sixty-three percent of community case-patients had at least one of these conditions. Nosocomial infection (48 cases [22%]) was independently associated with the placement of a central venous line (odds ratio, 30.9 [CI, 5.2 to 184.1]; P < 0.001), diabetes, congestive heart failure, and seizure disorder.
Conclusions: Several chronic conditions were independently associated with group B streptococcal disease, and most case-patients had at least one of these conditions. If group B streptococcal vaccines being developed for prevention of neonatal disease are protective in adults, a vaccination strategy targeting those at highest risk has the potential to substantially reduce the burden of invasive group B streptococcal infection in adults.
Previous case series have indicated that chronic underlying conditions such as diabetes mellitus, cancer, and alcoholism are common among adults with group B streptococcal disease [5-11]. Reports of population-based studies have indicated that the rate of disease is significantly higher among persons with diabetes mellitus [2, 12], human immunodeficiency virus (HIV) infection [2], and cancer [2, 12]. These studies have also indicated that a substantial proportion of adult infections are nosocomially acquired. However, the magnitude of risk associated with specific patient characteristics has not been evaluated in a controlled study adjusting for the effect of multiple factors. In addition, specific determinants of community-acquired and nosocomial disease have not been assessed.
Vaccines currently being developed for the prevention of neonatal group B streptococcal disease [13-16] may also be considered for the prevention of invasive infection in adults. Better knowledge of determinants of adult disease could be used to target such preventive efforts most effectively. We therefore did a casecontrol study comparing nonpregnant adults who had invasive group B streptococcal disease with patients hospitalized for other conditions. We report specific underlying conditions that were associated with community-acquired and nosocomial group B streptococcal infection and discuss the implications of these findings for the potential use of future vaccines.
Active surveillance for invasive group B streptococcal infection was done in 1991 and 1992 in an aggregate population of 6.6 million persons using previously described methods [1]. The population included all residents of three counties in California (Alameda, Contra Costa, and San Francisco); eight counties in Georgia (Cobb, Clayton, Dekalb, Douglas, Fulton, Gwinnett, Newton, and Rockdale); and Baltimore City and Baltimore County, Maryland. Briefly, regional surveillance staff made biweekly calls to infection-control practitioners or designated contacts in the microbiology laboratories serving all acute-care hospitals in the surveillance areas for reports of sterile-site (for example, blood or cerebrospinal fluid) isolates of group B streptococcus. A case report form requesting information on demographic characteristics, site of isolation, and clinical syndrome was completed for each identified case. To ensure complete reporting, periodic audits of all laboratories were done.
A case of invasive adult group B streptococcal disease was defined as isolation of group B streptococcus from a normally sterile site in a resident of a surveillance area who was 18 years of age or older and who was not pregnant or postpartum. If group B streptococcus was first isolated from a specimen obtained 2 or more days after hospital admission, the case was defined as nosocomial. Cases with positive cultures obtained from 1 June 1991 to 30 June 1992 in California and Georgia and from 1 November 1991 to 31 October 1992 in Maryland were eligible for inclusion.
Selection of Controls
For each case-patient, a listing of all patients hospitalized on the same day and of the hospital service to which they were admitted was obtained and reviewed. Controls were selected by identifying the three preceding patients admitted to the same general service (for example, medicine instead of oncology or surgery instead of orthopedic surgery) as the case-patient. If three appropriate controls could not be identified, admission lists for previous days were sequentially reviewed until three controls for each case-patient were enrolled.
Data Collection
We used standardized forms to abstract medical records for case-patients and controls. Information on demographic variables, outcome, outpatient medications, presenting signs and symptoms, underlying conditions, and the clinical syndrome associated with group B streptococcal infection was collected. For all cases, isolation of group B streptococcus from a sterile site was documented and information on isolation of other organisms from blood was obtained. For nosocomial cases, additional information was obtained on medications administered and procedures done in the hospital before the first positive group B streptococcal specimen was collected. For controls matched to case-patients with nosocomial infection, this additional information was abstracted for the same number of days after admission as for the matched case-patient.
Statistical Analysis
We used the chi-square test to compare proportions of categorical variables among case-patients. We did matched univariate and multiple conditional logistic regression analyses [17] using the Statistical Analysis System procedure PHREG [18] to estimate the risk for group B streptococcal disease associated with individual underlying conditions and exposures. Potential interaction among the variables associated with disease was evaluated by including two-way interaction and main-effect terms in multivariate models. We used stepwise selection, incorporating variables that were significant (P < equals 0.05) in the univariate analysis, to identify a final model for nosocomial disease. To ensure that the risk associated with the underlying conditions was assessed after we controlled for age, we forced a categorical variable that coded for age into the community-acquired model and then used stepwise selection to determine the other variables in the final model.
Proportions of case-patients and controls with selected demographic characteristics and underlying medical conditions are listed in Table 1. The age range for case-patients was 22 to 99 years (median age, 68 years), and the age range for controls was 18 to 99 years (median age, 60 years). Case-patients who died during the hospitalization that was studied died a median of 5 days after collection of the specimen from which group B streptococcus was isolated (range, 0 to 187 days). ARTICLE
Risk Factors for Group B Streptococcal Disease in Adults
Group B streptococcus (Streptococcus agalactiae), a major cause of neonatal sepsis and meningitis in the United States, is an important cause of invasive bacterial infection in adults. An estimated 7600 cases of group B streptococcal disease occur annually among persons 15 years of age and older in the United States [1]; the incidence among those 60 years of age or older is 18/100 000 persons per year [2]. Among nonpregnant adults, skin and soft-tissue infections and bacteremia of uncertain source are the most common manifestations of invasive disease. The clinical spectrum also includes urosepsis, pneumonia, peritonitis, meningitis, septic arthritis, and endocarditis [2]. Despite nearly universal sensitivity of the organism to penicillin [3, 4], approximately 20% of cases of adult group B streptococcal disease are fatal [2].
Methods
![]()
Top
Methods
Results
Discussion
Author & Article Info
References
Identification of Cases
Results
![]()
Top
Methods
Results
Discussion
Author & Article Info
References
Chart abstractions were completed for 219 of the 290 (76%) case-patients identified by surveillance (97 from Baltimore, 72 from the San Francisco metropolitan area, and 50 from the Atlanta metropolitan area) and for 645 matched controls from 54 hospitals (2.9 controls per case-patient). Seventy-one case-patients identified by surveillance were not included in the study for the following reasons: the hospital chart was not available for review (50 case-patients), the hospital did not participate in the study (9 case-patients), a sterile-site group B streptococcal culture could not be documented (5 case-patients), the patient was not admitted to the hospital (3 case-patients), the hospital closed (2 case-patients), or the patient died in the emergency department (2 case-patients). Information from the surveillance case report form indicates that the age and sex distribution and mortality rate of the cases not included did not significantly differ from those of the case-patients included in the study.
|
Characteristics of Invasive Group B Streptococcal Disease
Site of Isolation
Group B streptococcus was isolated from blood in 201 cases (92%). Other sites of isolation included synovial fluid (6 cases), peritoneal fluid (6 cases), pleural fluid (4 cases), and cerebrospinal fluid (2 cases). It was also isolated from an abscess, bone, bone marrow, bronchial washing, intervertebral disc-space fluid, gall bladder, and liver tissue (1 case each). More than one site of isolation could be reported for each case.
Polymicrobial Bacteremia
Polymicrobial bacteremia, defined as the isolation of other bacterial species from blood cultures collected on the same day as a positive blood culture for group B streptococcus, was identified in 53 of 201 case-patients (26%) with group B streptococcal bacteremia. Staphylococcus aureus was isolated from 24 case-patients and was the only additional organism isolated from 17 case-patients. The age distribution, mortality rate, and proportion of nosocomial cases were similar between case-patients with polymicrobial bacteremia and those with bacteremia caused only by group B streptococcus.
Clinical Syndromes
The clinical syndromes associated with group B streptococcal infection in case-patients are listed in Table 2. Seven of the 19 case-patients with cellulitis were women with a history of breast cancer in whom cellulitis was associated with invasive group B streptococcal infection. Five of these 7 case-patients had cellulitis of the arm or chest wall on the side of a mastectomy done 3 months to 12 years before admission, 1 had cellulitis of the chest wall opposite the site of the previous mastectomy, and 1 had cellulitis of the arm after axillary node dissection.
|
Characteristics Associated with In-Hospital Death
Age was associated with in-hospital mortality. Case-patients 65 years of age or older were significantly more likely to die of group B streptococcal infection than were younger case-patients (in-hospital mortality rates, 28% and 13%, respectively; P = 0.008). Although the overall mortality rate for patients with a clinical diagnosis of pneumonia was higher than the rate for other patients (41% and 18%, respectively; P = 0.009) and the mortality rate for patients with cellulitis was lower (0% and 23%, respectively; P = 0.02), it was not significantly associated with clinical diagnosis after we controlled for the effect of age.
Among case-patients with community-acquired bacteremia, those who had hypothermia on admission (temperature less than equals 36.1 °C) were significantly more likely to die during the hospitalization than case-patients who presented with fever (temperature more than equals 38.3 °C) or intermediate temperatures (mortality rates of 42%, 12%, and 21%, respectively; P = 0.01). This association remained after we controlled for age.
Risk Factors for Disease
Most patients with invasive group B streptococcal infection had chronic underlying medical conditions (Table 1). Ninety-three percent of case-patients and 77% of controls had at least one of the following conditions: diabetes mellitus, cancer, cardiovascular disease, chronic renal insufficiency, alcoholism, injecting drug use, HIV infection, neurologic disease, or cirrhosis.
In univariate analysis, advanced age was associated with disease; age 65 years or older was associated with a 1.8 times greater risk for disease (P < 0.001). Sex and race were not significantly associated with disease. Case-patients were not more likely than controls to have known HIV infection or anatomical asplenia or to have received an immunosuppressive medication in the 2 weeks before hospital admission.
Community-Acquired Infection
Table 3 lists the conditions found in univariate analysis to be significantly more common among case-patients with community-acquired infection than among matched controls. Age and variables significantly associated with disease in univariate analysis were included in a multivariate model, the results of which are also shown in Table 3. The association of age and group B streptococcal disease was of borderline statistical significance after we controlled for the effect of other underlying conditions in the multivariate model.
|
Sixty-three percent of case-patients (108 of 171) with community-acquired infection had at least one of the six underlying conditions that were significantly associated with disease in multivariate analysis, and 58% (100 of 181) had diabetes mellitus, previous stroke, cirrhosis, or breast cancer.
Nosocomial Disease
Forty-eight of the 219 case-patients (22%) had nosocomial infection and had been hospitalized for a median of 4 days (range, 2 to 366 days) before collection of the specimen from which group B streptococcus was isolated. Table 3 lists the variables significantly associated with disease in the univariate analysis and in the multivariate analysis that controlled for both age and the variables found to be significant in the univariate analysis.
Discussion
|
|---|
|
|
|---|
These results expand on the findings of previous case series [5-11] and population-based studies [2, 12], which indicated that diabetes mellitus, cancer, liver disease, alcoholism, and neurologic disease are common among adults with group B streptococcal disease. The most recent population-based study also compared the estimated incidence of group B streptococcal disease in persons with diabetes mellitus with that in the total population and found a significantly higher risk for disease among adults with diabetes across all age groups. However, the magnitude of risk was highest for diabetic patients younger than 45 years of age [2]. An elevated risk for disease was also noted for persons with HIV infection and young adults with cancer.
We did not identify a significant association between group B streptococcal disease and the presence of malignant disorders (other than breast cancer) or HIV infection in any age group. This may be partly attributable to our study design, which would tend to bias against finding a true association if it exists, because our control group of hospitalized persons probably had a higher prevalence of underlying conditions than the general population. Therefore, our failure to detect a significant association does not mean that a condition is not a risk factor for disease. Conversely, a significant association between a condition and group B streptococcal disease in our study suggests that an even stronger association might be found if case-patients were compared with members of the general population. In addition, although we included 219 cases in our study, this sample size may not have been sufficient to detect an association for rare conditions. Asplenia in particular is a rare condition that has been documented in several patients with group B streptococcal sepsis [11, 19-21].
The absence of an association with malignant disorders in general may also be a result of the heterogeneous nature of the conditions in this category. As previously suggested [22], it is possible that only a subset of patients with cancer are at increased risk for group B streptococcal infection. We collected information on type of cancer, presence of metastases, and previous receipt of chemotherapy or radiation treatment and did not find an association between solid tumors, hematologic malignancy, metastatic cancer, or previous cancer treatment and either community-acquired or nosocomial group B streptococcal infection.
Reports of population-based surveillance for invasive group B streptococcal disease have also indicated elevated rates of disease among men and black persons [1, 2, 12]. The absence of an association between these variables and disease in our analysis suggests that sex and race are not in themselves risk factors for disease but may be surrogate markers for the presence of other conditions.
We identified case-patients through laboratory-based surveillance for sterile-site isolates of group B streptococcus. This system would not identify persons with group B streptococcal infections from whom sterile-site cultures were not obtained. This may have introduced a detection bias by preferentially including patients who were more likely to seek medical attention or who were more likely to be suspected of having a potentially treatable infection by their health care provider. However, because our surveillance system was population-based, we believe that our case-patients were more likely to be representative of the population of persons with invasive group B streptococcal infection than patients identified by surveillance at a single hospital or group of hospitals.
We could not include 71 of the 290 patients identified by the surveillance system in the study, and this may also have introduced bias. However, available data on the patients who were not included suggest that these patients were not significantly different from patients enrolled in the study. Because blood or other sterile-site cultures may not have been obtained from controls, some patients with unrecognized group B streptococcal infection may have been misclassified as controls. Although we cannot exclude this possibility, we believe that the number of misclassified patients, if any, is small and that this type of bias would be unlikely to significantly affect our findings.
Our findings suggest potential areas for further investigation of the pathogenesis of invasive group B streptococcal infection in nonpregnant adults. Low titers of antibody to group B streptococcal polysaccharide capsular antigens have been seen in women whose neonates have group B streptococcal infection [23, 24], suggesting that low titers of passively transferred maternal antibody are associated with neonatal infection. Serum samples from persons with insulin-dependent diabetes have shown inefficient phagocytic activity against type II group B streptococcus in vitro. This deficiency was corrected by the addition of specific antibody [25]. To our knowledge, immunologic factors associated with group B streptococcal infection among persons with other underlying diseases have not been specifically addressed.
The increased risk for group B streptococcal infection associated with certain underlying conditions may be a result of factors other than or in addition to defects in humoral immunity. Group B streptococcus can colonize the skin [26], gastrointestinal tract [27, 28], and nasopharynx [26] and can cause urinary tract infections in adults [29]. Several of the conditions associated with group B streptococcal disease in our study, such as decubitus ulcers, neurogenic bladder, mastectomy, and stroke may predispose patients to infection by altering host defenses and allowing invasion of the organism from a site of colonization.
Identification of conditions associated with an increased risk for infection also has implications for the targeting of group B streptococcal polysaccharide-protein conjugate vaccines currently under development for prevention of neonatal infection. These vaccines have been shown to be more immunogenic than polysaccharide vaccines and have induced protection in animal models [16, 30-32]. The major serotypes associated with human disease, including serotype V, which only recently emerged as an important cause of group B streptococcal disease [33, 34], have been conjugated to carrier proteins [15, 16, 30-32, 35]. Although isolate collection was not a part of this study, researchers doing serotyping of invasive group B streptococcal isolates from patients identified by the laboratory-based surveillance system in Atlanta and Maryland during roughly the same period found that nearly all the adult group B streptococcal isolates tested were the serotypes included in candidate vaccines [33, 34]. The apparently rapid emergence of type V disease emphasizes the importance of continued surveillance as a complement to vaccine development.
If a vaccine that is protective in adults is developed, our results indicate that approximately 60% of adults with community-acquired infection could be targeted on the basis of underlying conditions associated with an increased risk for infection. In our analysis, age was an independent risk factor for infection and persons 65 years of age or older had a significantly higher in-hospital mortality rate than younger persons with group B streptococcal infection. An increased risk for death as a consequence of infection has been used as a criteria in recommendations for influenza and pneumococcal vaccines [36, 37] and suggests that this group may also benefit from preventive measures. Sixteen percent (28 of 171) of case-patients with community-acquired infection were younger than 65 years of age and did not have any of the underlying conditions that were associated with disease in multivariate analysis. Although several underlying conditions were also associated with nosocomial infection, preventive measures may be less effective in preventing nosocomial disease, especially if severely ill hospitalized patients acquire infection as a complication of invasive procedures.
We identified several underlying medical conditions that were significantly more common among patients with invasive group B streptococcal disease than other hospitalized persons. Further research on immunologic factors associated with adult group B streptococcal infection and demonstration of the immunogenicity and efficacy of future vaccines are necessary before recommendations for preventive strategies for adults can be developed. In addition, cost-effectiveness and costutility evaluations of adult immunization strategies would aid in setting priorities for preventive measures. Our results suggest, however, that if the group B streptococcal vaccines being developed for prevention of neonatal disease protect against adult disease, a targeted vaccination strategy for adults at increased risk could substantially reduce the morbidity and mortality of this serious bacterial infection.
Drs. Schuchat and Wenger and Ms. Hilsdon: Mailstop C-09, Centers for Disease Control and Prevention, Atlanta, GA 30333.
Dr. Farley: Infectious Diseases Service, Veterans Affairs Medical Center (151), 1670 Clairmont Road, Decatur, GA 30033.
Dr. Harrison: Department of International Health, Johns Hopkins University School of Hygiene and Public Health, 615 North Wolfe Street, Baltimore, MD 21205.
Dr. Reingold: Division of Public Health, Biology, and Epidemiology, University of California at Berkeley, 140 Warren Hall #7360, Berkeley, CA 94720.
Author and Article Information
|
|---|
|
|
|---|
References
|
|---|
|
|
|---|
1. Zangwill KM, Schuchat A, Wenger JD. Group B streptococcal disease in the United States, 1990: report from a multistate active surveillance system. MMWR CDC Surveill Summ. 1992; 41:25-32.
2. Farley MM, Harvey RC, Stull T, Smith JD, Schuchat A, Wenger JD, et al. A population-based assessment of invasive disease due to group B Streptococcus in nonpregnant adults. N Engl J Med. 1993; 328:1807-11.
3. Berkowitz K, Regan JA, Greenberg E. Antibiotic resistance patterns of group B streptococci in pregnant women. J Clin Microbiol. 1990; 28:5-7.
4. Edwards MS, Baker CJ.Streptococcus agalactiae (Group B streptococcus). In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases. 4th ed. New York: Churchill Livingstone; 1995:1835-45.
5. Gallagher PG, Watanakunakorn C. Group B streptococcal bacteremia in a community teaching hospital. Am J Med. 1985; 78:795-800.
6. Verghese A, Mireault K, Arbeit RD. Group B streptococcal bacteremia in men. Rev Infect Dis. 1986; 8:912-7.
7. Lerner PI, Gopalakrishna KV, Wolinsky E, McHenry MC, Tan JS, Rosenthal M. Group B streptococcus (S. agalactiae) bacteremia in adults: analysis of 32 cases and review of the literature. Medicine (Baltimore). 1977; 56:457-73.
8. Bayer AS, Chow AW, Anthony BF, Guze LB. Serious infections in adults due to group B streptococci. Clinical and serotypic characterization. Am J Med. 1976; 61:498-503.
9. Dworzack DL, Hodges GR, Barnes WG, Rosett W. Group B streptococcal infections in adult males. Am J Med Sci. 1979; 277:67-73.
10. Opal SM, Cross A, Palmer M, Almazan R. Group B streptococcal sepsis in adults and infants. Contrasts and comparisons. Arch Intern Med. 1988; 148:641-5.
11. Small CB, Slater LN, Lowy FD, Small RD, Salvati EA, Casey JL. Group B streptococcal arthritis in adults. Am J Med. 1984; 76:367-75.
12. Schwartz B, Schuchat A, Oxtoby MJ, Cochi SL, Hightower A, Broome CV. Invasive group B streptococcal disease in adults. A population-based study in metropolitan Atlanta. JAMA. 1991; 266:1112-4.
13. Baker CJ, Rench MA, Kasper DL. Response to type III polysaccharide in women whose infants have had invasive group B streptococcal infection. N Engl J Med. 1990; 322:1857-60.
14. Paoletti LC, Wessels MR, Rodewald AK, Shroff AA, Jennings HJ, Kasper DL. Neonatal mouse protection against infection with multiple group B streptococcal (GBS) serotypes by maternal immunization with a tetravalent GBS polysaccharide-tetanus toxoid conjugate vaccine. Infect Immun. 1994; 62:3236-43.
15. Madoff LC, Paoletti LC, Tai JY, Kasper DL. Maternal immunization of mice with group B streptococcal type III polysaccharide-ß C protein conjugate elicits protective antibody to multiple serotypes. J Clin Invest. 1994; 94:286-92.
16. Wessels MR, Paoletti LC, Rodewald AK, Michon F, DiFabio J, Jennings HJ, et al. Stimulation of protective antibodies against type Ia and Ib group B streptococci by a type Ia polysaccharide-tetanus toxoid conjugate vaccine. Infect Immun. 1993; 61:4760-6.
17. Breslow NE, Day NE. Statistical methods in cancer research. Volume 1The analysis of casecontrol studies. IARC Sci Publ. 1980; 32:248-79.
18. SAS technical report P-229. SAS/STAT Software: Changes and enhancements, release 6.07. Cary, NC: SAS Institute; 1992.
19. Gallagher PG, Watanakunakorn C. Group B streptococcal endocarditis: report of seven cases and review of the literature, 1962-1985. Rev Infect Dis. 1986; 8:175-88.
20. Miller JD. Overwhelming group B streptococcal sepsis after splenectomy in an adult. South Med J. 1982; 75:76.
21. Finnegan OC, Hawkey PM. Overwhelming post-splenectomy infection with group B Streptococcus. Postgrad Med J. 1981; 57:202-3.
22. Mathew P. Group B streptococcal disease in adults [Letter]. N Engl J Med. 1993; 329:1658.
23. Baker CJ, Kasper DL. Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection. N Engl J Med. 1976; 294:753-6.
24. Baker CJ, Edwards MS, Kasper DL. Role of antibody to native type III polysaccharide of group B Streptococcus in infant infection. Pediatrics. 1981; 68:544-9.
25. Baker CJ, Webb BJ, Kasper DL, Edwards MS. The role of complement and antibody in opsonophagocytosis of type II group B streptococci. J Infect Dis. 1986; 154:47-54.
26. Casey JI, Maturlo S, Albin J, Edberg SC. Comparison of carriage rates of group B streptococcus in diabetic and nondiabetic persons. Am J Epidemiol. 1982; 116:704-8.
27. Dillon HC Jr, Gray E, Pass MA, Gray BM. Anorectal and vaginal carriage of group B streptococci during pregnancy. J Infect Dis. 1982; 145:794-9.[Medline]
28. Anthony BF, Carter JA, Eisenstadt R, Rimer DG. Isolation of group B streptococci from the proximal small intestine of adults. J Infect Dis. 1983; 147:776.
29. Mu&164;oz P, Coque T, Cr&130;ixems Rodriquez M, Bernaldo de Quir&162;s JC, Moreno S, Bouza E. Group B Streptococcus: a cause of urinary tract infection in nonpregnant adults. Clin Infect Dis. 1992;14:492-6.[Medline]
30. Lagergard T, Shiloach J, Robbins JB, Schneerson R. Synthesis and immunological properties of conjugates composed of group B streptococcus type III capsular polysaccharide covalently bound to tetanus toxoid. Infect Immun. 1990; 58:687-94.
31. Paoletti LC, Wessels MR, Michon F, DiFabio J, Jennings HJ, Kasper DL. Group B streptococcus type II polysaccharide-tetanus toxoid conjugate vaccine. Infect Immun. 1992; 60:4009-14.
32. Paoletti LC, Kasper DL, Michon F, DiFabio J, Holme K, Jennings HJ, et al. An oligosaccharide-tetanus toxoid conjugate vaccine against type III group B Streptococcus. J Biol Chem. 1990; 265:18278-83.
33. Harrison LH, Dwyer DM, Johnson JA. Emergence of serotype V group B streptococcal infection among infants and adults [Letter]. J Infect Dis. 1995; 171:513.
34. Blumberg HM, Modansky M, Stephens DS, Elliott J, Facklam R, Wenger JD, et al. Emergence of invasive serotype V group B streptococcal disease [Abstract]. Clin Res. 1994; 42:298A.
35. Wessels MR, Paoletti LC, Pinel J, Kasper DL. Immunogenicity and protective activity in animals of a type V group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine. J Infect Dis. 1995; 171:879-84.
36. Pneumococcal polysaccharide vaccine. MMWR Morb Mortal Wkly Rep. 1989; 38:64-76.
37. Prevention and control of influenza: Part I, vaccines. Recommendations of the Advisory Committee on Immunization Practives (ACIP). MMWR. 1993; 42(RR-6):1-14.
This article has been cited by other articles:
![]() |
C. R. Phares, R. Lynfield, M. M. Farley, J. Mohle-Boetani, L. H. Harrison, S. Petit, A. S. Craig, W. Schaffner, S. M. Zansky, K. Gershman, et al. Epidemiology of Invasive Group B Streptococcal Disease in the United States, 1999-2005 JAMA, May 7, 2008; 299(17): 2056 - 2065. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. R. Bolduc and L. C. Madoff The group B streptococcal alpha C protein binds {alpha}1 1-integrin through a novel KTD motif that promotes internalization of GBS within human epithelial cells Microbiology, December 1, 2007; 153(12): 4039 - 4049. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. C. Auperin, G. R. Bolduc, M. J. Baron, A. Heroux, D. J. Filman, L. C. Madoff, and J. M. Hogle Crystal Structure of the N-terminal Domain of the Group B Streptococcus Alpha C Protein J. Biol. Chem., May 6, 2005; 280(18): 18245 - 18252. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Tissi, M. Puliti, F. Bistoni, P. Mosci, T. R. Kozel, and A. Vecchiarelli Glucuronoxylomannan, the Major Capsular Polysaccharide of Cryptococcus neoformans, Inhibits the Progression of Group B Streptococcal Arthritis Infect. Immun., November 1, 2004; 72(11): 6367 - 6372. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Puliti, C. von Hunolstein, F. Bistoni, G. Orefici, and L. Tissi Inhibition of Nitric Oxide Synthase Exacerbates Group B Streptococcus Sepsis and Arthritis in Mice Infect. Immun., August 1, 2004; 72(8): 4891 - 4894. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Baron, G. R. Bolduc, M. B. Goldberg, T. C. Auperin, and L. C. Madoff Alpha C Protein of Group B Streptococcus Binds Host Cell Surface Glycosaminoglycan and Enters Cells by an Actin-dependent Mechanism J. Biol. Chem., June 4, 2004; 279(23): 24714 - 24723. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Puliti, C. von Hunolstein, C. Verwaerde, F. Bistoni, G. Orefici, and L. Tissi Regulatory Role of Interleukin-10 in Experimental Group B Streptococcal Arthritis Infect. Immun., June 1, 2002; 70(6): 2862 - 2868. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Puliti, F. Bistoni, C. von Hunolstein, G. Orefici, and L. Tissi Severity of Group B Streptococcal Arthritis in Selected Strains of Laboratory Mice Infect. Immun., January 1, 2001; 69(1): 551 - 555. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. F. Bohnsack, S. Takahashi, L. Hammitt, D. V. Miller, A. A. Aly, and E. E. Adderson Genetic Polymorphisms of Group B Streptococcus scpB Alter Functional Activity of a Cell-Associated Peptidase That Inactivates C5a Infect. Immun., September 1, 2000; 68(9): 5018 - 5025. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Sellin, C. Olofsson, S. Håkansson, and M. Norgren Genotyping of the Capsule Gene Cluster (cps) in Nontypeable Group B Streptococci Reveals Two Major cps Allelic Variants of Serotypes III and VII J. Clin. Microbiol., September 1, 2000; 38(9): 3420 - 3428. [Abstract] [Full Text] |
||||
![]() |
S. J. Schrag, S. Zywicki, M. M. Farley, A. L. Reingold, L. H. Harrison, L. B. Lefkowitz, J. L. Hadler, R. Danila, P. R. Cieslak, and A. Schuchat Group B Streptococcal Disease in the Era of Intrapartum Antibiotic Prophylaxis N. Engl. J. Med., January 6, 2000; 342(1): 15 - 20. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Tissi, M. Puliti, R. Barluzzi, G. Orefici, C. von Hunolstein, and F. Bistoni Role of Tumor Necrosis Factor Alpha, Interleukin-1beta , and Interleukin-6 in a Mouse Model of Group B Streptococcal Arthritis Infect. Immun., September 1, 1999; 67(9): 4545 - 4550. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Gardam, D. E. Low, R. Saginur, and M. A. Miller Group B Streptococcal Necrotizing Fasciitis and Streptococcal Toxic Shock-Like Syndrome in Adults Arch Intern Med, August 10, 1998; 158(15): 1704 - 1708. [Abstract] [Full Text] |
||||
![]() |
A. Schuchat Epidemiology of Group B Streptococcal Disease in the United States: Shifting Paradigms Clin. Microbiol. Rev., July 1, 1998; 11(3): 497 - 513. [Abstract] [Full Text] [PDF] |
||||
![]() |
Risk Factors for Adult Group B Strep Journal Watch Dermatology, October 1, 1995; 1995(1001): 17 - 17. [Full Text] |
||||
![]() |
RISK FACTORS FOR ADULT GROUP B STREP Journal Watch (General), September 19, 1995; 1995(919): 4 - 4. [Full Text] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||